During a live event, Patrick Moore, MD, discussed the superior efficacy with ide-cel vs standard care in relapsed/refractory ...
As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback